Boots UK’s display ad for its Dual Defense cold and flu symptom nasal spray was unlikely to deceive consumers to think it could prevent infection, UK Advertising Standards Authority says, which found that text in a poster ad sufficiently "conceptualized" the claim.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2017

The $50m deal adds a homeopathic brand to Mylan's portfolio that will lead its US consumer lineup; ProPhase will focus on dietary supplements; leave behind seasonal-demand products.

Mylan could tap respiratory product experience to develop line extensions to the homeopathic product, now seen as the centerpiece of its US consumer business.